Read more
This book is a compilation of the invited papers, which were presented at the Fourth European Symposium on Radiopharmacy and Radiopharmaceuticals, which was held in Baden, Switz- land, 1-4 May, 1991. The First and Third Symposia on Radiopharmacy and Radiopharmaceuticals (Elsinore, Denmark, 1983, 1987) concentrated on the safety and efficacy of radiopharmaceuticals, whereas this Fourth Symposium to some extent followed up the subject of the Second Symposium (Cambridge, UK, 1985): recent developments in radiopharmacy and current research on radiopharmaceuticals. The symposium was organized by the Radiopharmacy Group of the Swiss Society of Medical Radiology (Section Nuclear Medicine) under the auspices of the task group on radiopharmaceu- cals of the European Association of Nuclear Medicine (EANM). The organizing committee consisted of the cochairmen Drs. P.A. Schubiger (Paul Scherrer Institute (PSI), Villigen) and G. Westera (University Hospital, ZiJrich) and the members H.-F. Beer, P. Bl~iuenstein, P. Hasler (all PSI) and H. M~icke (Cantonal Hospital, Basel). The subjects of this Symposium ranged from isotope production to clinical testing of radioph- maceuticals, including the organisational prerequisites. In addition, the development of new radiopharmaceuticals and of PET radiopharmacy, and the concomittant ongoing evolution of regulatory guidelines by national (various European countries, USA) and international (EC) authorities, induced us to honor the vivid interest in this subject and to make it an important part of this symposium.
List of contents
1. Future development of radiopharmaceuticals.- One: Brain receptor ligands.- 2. Necessary conditions for a multicenter study with a new radiopharmaceutical. Example: 123 I-Iomazenil.- 3. Design and evaluation of new receptor ligands exemplified by recent developments in the pharmacology of the benzodiazepine receptor.- 4. Studies on substituted benzamides as brain dopamine receptor imaging agent.- Two: Technetium-99m and other radionuclide generators.- 5. Cell labeling in radiopharmacy: what can radiolabeled monoclonal antibodies offer?.- 6. Automated systems for the preparation of Tc-kits in hospitals.- 7. New radiopharmaceuticals based on Technetium.- 8. The development of new radionuclide generator systems for nuclear medicine applications.- Three: Positron Emission Tomography.- 9. Production and application of oxygen-15; radiopharmacy aspects.- 10. Clinical aspects of positron emission tomography.- 11. Carbon-11 radiopharmaceuticass - radiopharmacy aspects.- 12. Production and distribution of 18F-radiopharmaceuticals - 2-deoxy-2[18F]fluoro-D-Glucose - radiopharmaceutic aspects.- 13. Preclinical data necessary to assess PET examinations.- Four: Rules and regulations.- 14. EEC directives and radiopharmaceuticals: the point of view of the radiopharmaceutical industry.- 15. European regulations and guidelines for the registration of radiopharmaceuticals.- 16. General guidelines for the quality assurance and quality control of short-lived radiopharmaceuticals.- 17. Legal and regulatory aspects of PET radiopharmaceuticals in the USA.- Five: Education.- 18. The development of a co-ordinated training programme in radiopharmacy in Europe.- 19. Experiences in postgraduate education of radiochemists and radiopharmacists at Berlin- Buch.- Six: Appendix.- 20. Monoclonalchimeric antibodies to HIV-1 - Clinical perspectives.- 21. Tracer technique - the Swiss story.
Report
'...results in a publication that should serve as a useful resource for radioharmacists, radiopharmaceutical scientists, and nuclear medicine clinicians working in academic and research environments.' Clinical Nuclear Medicine Sep. 1992
